Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Georgiamune has raised $92.7M in total funding. The most recent round was Series B. The last funding was announced in August 2026.
Georgiamune's investors include General Catalyst, Catalio Capital Management, Alexandria Venture Investments, Mubadala Capital Ventures, Parker Institute for Cancer Immunotherapy.
Georgiamune is headquartered in Gaithersburg, United States.
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Georgiamune is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Georgiamune — Funding & Investors." VCBacked, August 17, 2026, https://www.vcbacked.co/company/georgiamune. Accessed September 14, 2026.
VCBacked. (2026). Georgiamune — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/georgiamune
{{cite web |title=Georgiamune — Funding & Investors |url=https://www.vcbacked.co/company/georgiamune |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated